The Pfizer and Johnson & Johnson-backed cancer treatment developer is eyeing expansion in Asia after receiving $40m in additional series D funding.
US-based oncology therapy technology developer Reflexion secured $40m on Tuesday from healthcare-focused investment firm Ally Bridge Group to expand a series D round featuring pharmaceutical firms Pfizer and Johnson & Johnson to $150m.
The company said it raised $110m of series D funding across 2020, including $100m from investors including Pfizer Ventures and Johnson & Johnson Innovation – JJDC, the respective investment vehicles for Pfizer and Johnson & Johnson, in April 2020.
Canada’s Public Sector Pension Investment Board led
